ProPhase Labs

12/09/05

Quigley Pharma Compound QR-442 Shown to Delay Onset of Disease and Lower Disease Severity in Animal Multiple Sclerosis Model

DOYLESTOWN, PA (December 9, 2005) The Quigley Corporation (NASDAQ: QGLY), wholly owned subsidiary Quigley Pharma announced today the results of a mouse multiple sclerosis model (EAE) study which has shown that the QR-442, a naturally derived compound was found to delay onset of disease as well as considerably lowering severity.

[More]

12/08/05

Quigley Pharma's Compound QR-336 Shown to Protect Mice From Lethal Exposure to Ionizing Radiation

80% of Treated Mice Survived; Potential Protective Agent Against Radiation Exposure.

[More]

12/06/05

Quigley Pharma Issued An Investigational New Animal Drug (INAD) Number By The FDA To Study Its Anti-Viral Compound For Avian Flu In Pigs

Pigs May Serve as Intermediate Hosts for Virus & Source of Transmission to Humans

[More]

12/01/05

Quigley Pharma's Compound QR-441 Shown to Increase Protectivity Against H5N1 Avian Flu When Impregnated into Commercially Available Respiratory Face Masks

DOYLESTOWN, PA (December 1, 2005) The Quigley Corporation (NASDAQ: QGLY), announced today Quigley Pharma's QR-441 compound sprayed on respiratory mask air filters has been tested against avian influenza virus (H5N1) and human influenza virus (H3N2).

[More]

11/09/05

The FDA Issues Four Additional Investigational New Animal Drug (INAD) Numbers To Quigley Pharma To Study Its Anti-Viral Compound QR-441A On Companion Animals (Pets)

DOYLESTOWN, PA (November 9, 2005) The Quigley Corporation (NASDAQ: QGLY), announced today that on November 7th. 2005, its wholly owned subsidiary Quigley Pharma received four additional Investigational New Animal Drug (INAD) numbers, from the Center for Veterinary Medicine of the Food and Drug Administration.

[More]

11/08/05

Quigley Pharma is Issued Three Investigational New Animal Drug (INAD) Numbers by the FDA To Study Its Anti-Viral Compound On Avian Flu

The Threat of Avian Flu Drives Research Into Veterinary Application
For QR-441A

[More]

11/03/05

The Quigley Corporation Retains Brocair Partners LLC To Provide Strategic Option Evaluations For Quigley Pharma's QR-340 Scar Formula

DOYLESTOWN, PA (November 3, 2005) The Quigley Corporation (NASDAQ: QGLY), announced today that the Company has retained New York-based Brocair Partners LLC to provide assistance to management in evaluating various strategic options for Quigley Pharma's QR-340 Scar Formula.

[More]

10/26/05

Quigley Pharma's Compound QR-441 Shown to Increase Protectivity Against H5N1 Avian Flu When Impregnated into Commercially Available Respiratory Face Masks

DOYLESTOWN, PA (October 26, 2005) Quigley Pharma, a wholly owned subsidiary of Quigley Corporation (NASDAQ: QGLY), announced today the completion of an animal model study of its naturally derived compound QR-442. The murine experimental autoimmune encephalomyelitis (EAE) is an animal model for multiple sclerosis.

[More]

10/18/05

Pre-Clinical Toxicity Studies Show Quigley Pharma's Diabetic Neuropathy Formulation QR-333 Is Safe For Topical Application

DOYLESTOWN, PA (October 18, 2005) Quigley Pharma, a wholly owned subsidiary of the Quigley Corporation (NASDAQ: QGLY), announced today that two pre-clinical toxicity studies of QR-333, a topical compound for the treatment of diabetic neuropathy, was determined to be safe for topical application. QR-333 is designed and formulated to significantly decrease the symptoms associated with diabetic peripheral neuropathy.

[More]

09/07/05

Journal of Diabetes And ItÃƒÂ¢Ã¢â€šÂ¬Ã¢â€žÂ¢s Complications Publishes Favorable Study Addressing Quigley PharmaÃƒÂ¢Ã¢â€šÂ¬Ã¢â€žÂ¢s Diabetic Neuropathy Formulation QR-333

Topical Compound May Safely Offer Relief for The
Treatment of Symptomatic Diabetic Peripheral Neuropathy

[More]

08/01/05

The Quigley Corporation Announces Positive In-Vitro Study Results of its QR440 Compound Support Conclusions of Previous Animal Study Findings

Testing Shows Botanical Anti-Inflammatory Compound Inhibits Tumor Necrosis Factor
Alpha and May Have Disease-Modifying Potential

[More]

06/28/05

The Quigley Corporation Announces Results of Animal Model Inflammation Studies of Its QR440 Botanical, Anti-Inflammatory Compound

-- Testing Underway for Potential Alternative in Wake of COX-2 Inhibitor Issues -